Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib in Ibrutinib Exposed Patients With CLL
NCT06757647Phase 2Recruiting
- Start
- May 2025
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
A Phase 2 trial of acalabrutinib tablet (Variant 1) in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL). Started May 2025; status: recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT06757647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06757647.